Your session is about to expire
← Back to Search
Study Summary
This trialis testing a drug for people with advanced cancer to see if it's safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.You are expected to live for at least 12 weeks.My organs are functioning well.My cancer has spread to my brain and is causing symptoms.Your heart's electrical activity takes longer than normal to reset, or you have a condition that causes your heart to take longer to reset.My doctor thinks experimental therapy is a good option for me.My cancer is advanced or has spread to other parts of my body, excluding brain cancer.I am a poor metabolizer according to the CYP2D6 test.I have advanced cancer in the colon, breast (triple negative), ovary, uterus, soft tissue, or pancreas.My breast cancer is triple negative and has come back or not responded to treatment.I am not pregnant or nursing.I have advanced ovarian cancer and can be treated with Gemzar, even if I've had it before.My endometrial cancer is advanced and didn't respond to at least one chemotherapy.My pancreatic cancer is advanced and has not responded to at least one chemotherapy treatment.My colorectal cancer is confirmed to be advanced or has spread.My STS has spread or is advanced, and I've had chemotherapy that didn't work.I have undergone a bone marrow transplant.I have received radiation therapy to more than a quarter of my bone marrow.I have not had any active cancer in the past year, except for certain non-aggressive types considered cured.I have had 1-4 treatments for my advanced or spread cancer.I have high grade serous ovarian cancer and will be tested for specific genetic markers.You have a positive test for HIV or have chronic active hepatitis A, B, or C.You have tumor growth that can be measured using specific guidelines for evaluating solid tumors.
- Group 1: Part A: LY2880070 with Gemcitabine
- Group 2: Part B:LY2880070 and Gemcitabine (Ovarian)
- Group 3: Part B: LY2880070 and Gemcitabine (Endometrial)
- Group 4: Part A: LY2880070
- Group 5: Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))
- Group 6: Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)
- Group 7: Part A: LY2880070 (Metabolism Phenotype)
- Group 8: Part B: LY2880070 and Gemcitabine (Colorectal)
- Group 9: Part B: LY2880070 and Gemcitabine (Pancreatic)
- Group 10: Part B: LY2880070 and Gemcitabine (Breast)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there multiple venues in Canada where this research project is being conducted?
"This ongoing medical trial is available at 9 locations, including Montreal, Edmonton and Detroit. It would be prudent to choose the nearest study site so as to limit your transportation burden should you decide to join."
Does this experiment still accept volunteers?
"That is correct. According to clinicaltrials.gov, the trial which was originally posted on May 16th 2016 has recently resumed recruiting efforts and seeks 229 patients from 9 different locations."
To which maladies is Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS)) commonly deployed?
"Part B: LY2880070 and Gemcitabine (Soft tissue sarcoma (STS)) are indicated for use in small cell lung cancer treatment, but may also be useful to treat other carcinomas such as head and neck cancers, pancreatic adenocarcinoma locally advanced, or cervical tumours."
What is the maximum capacity for enrollment in this research project?
"Correct. According to clinicaltrials.gov, this study has been recruiting since May 16th 2016 and was last updated on January 11th 2023. The protocol requires the enrolment of 229 participants from 9 different medical sites."
Are there any other research projects that have tested the efficacy of Part B: LY2880070 and Gemcitabine when treating Soft Tissue Sarcoma (STS)?
"Currently, 416 trials assessing the efficacy of Part B: LY2880070 and Gemcitabine (Soft tissue sarcoma (STS)) are in progress with 127 at Phase 3. While Adelaide, South Australia has the most studies devoted to this research endeavor, there remain 23323 clinical trial sites around the world investigating Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))."
Share this study with friends
Copy Link
Messenger